BiotechTube

Lysozyme hydrochloride + Placebo

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

COPD

Conditions

COPD

Trial Timeline

Aug 1, 2012 → Mar 1, 2015

NCT ID
NCT01645800

About Lysozyme hydrochloride + Placebo

Lysozyme hydrochloride + Placebo is a approved stage product being developed by Eisai for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT01645800. Target conditions include COPD.

What happened to similar drugs?

20 of 20 similar drugs in COPD were approved

Approved (20) Terminated (5) Active (0)
✅Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
✅Arformoterol (Brovana) + PlaceboSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)AstraZenecaApproved
✅ACL/FOR + PlaceboAstraZenecaApproved
✅Aclidinium Bromide + PlaceboAstraZenecaApproved
✅Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.AstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01645800ApprovedCompleted

Competing Products

20 competing products in COPD

See all competitors
ProductCompanyStageHype Score
Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
43
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
Arformoterol (Brovana) + PlaceboSumitomo PharmaApproved
43
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + PlaceboSumitomo PharmaPhase 3
40
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + PlaceboSumitomo PharmaPhase 2
35
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
35
Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterolSumitomo PharmaPhase 2
35
Levalbuterol HCl + Levalbuterol HCl + Albuterol Sulfate + PlaceboSumitomo PharmaPhase 3
40
Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol TurbuhalerAstraZenecaPhase 1
29
AZD2115 + Placebo + Indacaterol + Indacaterol + TiotropiumAstraZenecaPhase 2
35
RoflumilastAstraZenecaPhase 2/3
38
Aclidinium bromide + PlaceboAstraZenecaPhase 3
40
RoflumilastAstraZenecaPre-clinical
26
Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)AstraZenecaApproved
43
AZD7624 + Placebo to matchAstraZenecaPhase 1
29
Roflumilast + PlaceboAstraZenecaPhase 3
40
Aclidinium bromide 100 μg bid + Aclidinium bromide 200 μg bid + Aclidininum bromide 400 μg bid + Placebo + Formoterol 12 μg bidAstraZenecaPhase 2
35
ACL/FOR + PlaceboAstraZenecaApproved
43
TozorakimabAstraZenecaPhase 2
35
AZD1981 + PlaceboAstraZenecaPhase 2
35